NCT05990751View on ClinicalTrials.gov

Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 19, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2041

Conditions
Neuroblastoma
Interventions
BIOLOGICAL

GD2 CAR T cells

The GD2 CAR T cells target GD2 positive cells. The cells also express transgenes that aim to increase their resistance within the tumour microenvironment.

Trial Locations (1)

Unknown

RECRUITING

Great Ormond Street Hospital, London

All Listed Sponsors
lead

University College, London

OTHER